EIRX Therapeutics, an Irish biotechnology company conducting research into genomics, has received £3 million (€3.8 million) in funding.

The investors are venture capital company 3i, Enterprise Ireland and AIM listed World Life Sciences. Enterprise Ireland is investing in the company for the second time. EiRx Therapeutics is carrying out research and development in genomics as applied to a key biological process known as apoptosis. This is also called "programmed cell death", a natural process of cell death that operates continuously in the body.